May 29, 2016
ORLANDO, Fla. — In patients at high-risk for adrenal malignancy, 18F-fluorodeoxyglucose-PET/CT imaging should be used with clinical judgment because of low sensitivity and specificity in this population, according to study findings presented here.
In a retrospective study, Danae Delivanis, MD, a second-year endocrine fellow at Mayo Clinic, and colleagues examined the performance of 18F-fluorodeoxyglucose(18FDG)-PET/CT imaging in a population at high risk for adrenal malignancy. The researchers evaluated data from 352 patients (62.5% men; median age, 68 years; age range, 18-91 years) referred for adrenal biopsies due to suspected or confirmed extra-adrenal malignancy between 1994 and 2014. Malignant adrenal lesions were present in 223 cases and benign lesions in 129. Histology yielded the reference standard in all patients.